Immunome, Inc.

NASDAQ:IMNM

Biotechnology

Healthcare
$16.78 -2.26%

-$0.42 today

Market cap
$1.98B
Beta
2.07
P/E (TTM)
-9.1
EPS (TTM)
-$1.99
52W Low $7.96High $27.65

Volume 1.41M

Average 1.23M

IMNM Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Immunome, Inc.NASDAQ: IMNM

Operating Expenses · Q3 FY2026 · quarter ended Sep 2026

Operating expenses growth accelerates

Q3 FY2026 operating expenses of $90.36M rose 725.6% year over year, ahead of the +54.6% change in trailing-twelve-month operating expenses. Sequentially, it rose 15.6% from the prior quarter. Over 3 fiscal years it compounded at +80.8% a year.

Context

  • Operating expenses amounted to 3142.2% of revenue in FY2025, down 340.2 pp from a year earlier.
  • Operating expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +725.6% holds above the trailing-twelve-month pace of +54.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$90.36M+15.6% QoQ
Last fiscal yearDec 2025
$218.1M-30.7% YoY
LTMSep 2026
$299.94M+54.6% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+725.6%——
1 year-30.7%——
3-year CAGR+80.8%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
218.1M USD
Year-over-year change
-30.7%
4-year CAGR
+71.5%

Operating Expenses vs competitors

How IMNM compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +54.6% is the 4th highest of 11, against a peer median of +34.3%.
  • Over three fiscal years its annual growth of +80.8% compares with a peer median of +19.3%.
IMNM Competitors
Operating Expenses for IMNM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMCRImmunocore Holdings plcLTM Mar 2026$410.51M USD+8.6%+21.4%106.4%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$333.75M USD+278.1%+101.5%297994.6%
IMNMImmunome, Inc.LTM Sep 2026$299.94M USD+54.6%+80.8%—
IMTXImmatics N.V.LTM Mar 2026€250M EUR+22.1%+17.2%670.3%
BCYCBicycle Therapeutics plcLTM Mar 2026$234.87M USD+104.1%+34.7%369.9%
STROSutro Biopharma, Inc.LTM Mar 2026$213.41M USD-32.3%+2.0%214.2%
MGNXMacroGenics, Inc.LTM Mar 2026$173.51M USD-10.6%-12.1%110.5%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$156.87M USD+11.7%+68.8%—
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$47.9M USD+53.4%+9.6%—
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$39.45M USD+46.4%-12.9%—
IMMXImmix Biopharma, Inc.LTM Mar 2026$35.95M USD+65.2%+48.4%—
Peer median (excluding IMNM) —+34.3%+19.3%292.1%

Competitors are the stored peer set for IMNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0014.02M9.04M6.94M
Cost of Revenue00002.96M
Gross Profit0014.02M9.04M3.99M
Gross Margin——100.0%100.0%57.4%
Research & Development14.11M23.27M23.09M129.54M174.33M
Selling, General & Admin11.09M13.63M19.66M32.96M43.77M
Operating Expenses25.2M36.9M123.55M314.84M218.1M
Depreciation & Amortization755K631K728K2.1M2.96M
EBITDA(23.95M)(36.26M)(28M)(151.35M)(209.44M)
EBITDA Margin——-199.7%-1674.1%-3017.4%
Operating Income(25.2M)(36.9M)(109.53M)(305.8M)(214.11M)
Operating Margin——-781.4%-3382.4%-3084.8%
Interest Income10K5K2.72M12.84M11.72M
Interest Expense10K5K000
Other Income / Expenses493K5K2.72M12.84M1.72M
Income Before Tax(24.71M)(36.9M)(106.81M)(292.96M)(212.39M)
Pre-Tax Margin——-761.9%-3240.4%-3060.0%
Income Tax Expense00000
Net Income(24.71M)(36.9M)(106.81M)(292.96M)(212.39M)
Net Margin——-761.9%-3240.4%-3060.0%
EPS (Basic)(2.14)(3.09)(5.38)(5.00)(2.43)
EPS (Diluted)(2.14)(3.09)(5.38)(5.00)(2.43)
Weighted Avg Shares11.54M12.13M19.84M58.64M87.35M
Weighted Avg Shares (Diluted)11.54M12.13M19.84M58.64M87.35M

Immunome, Inc.

NASDAQ:IMNM

Intrinsic Alpha fair value

Locked

Current Price

$16.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.